ACUTA CAPITAL PARTNERS, LLC - Q3 2023 holdings

$149 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 46 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 237.5% .

 Value Shares↓ Weighting
TSHA NewTAYSHA GENE THERAPIES INC$12,096,2463,827,926
+100.0%
8.11%
PRAX BuyPRAXIS PRECISION MEDICINES I$7,669,350
+56.9%
4,485,000
+5.5%
5.14%
+55.2%
NewRAYZEBIO INC$7,649,476344,571
+100.0%
5.13%
SRPT NewSAREPTA THERAPEUTICS INCcall$7,580,650550
+100.0%
5.08%
RCKT BuyROCKET PHARMACEUTICALS INC$7,417,380
+21.9%
362,000
+18.2%
4.97%
+20.6%
BuyVENTYX BIOSCIENCES INC$7,132,743
+47.6%
205,377
+39.4%
4.78%
+46.0%
BuyHILLEVAX INC$3,635,791
+235.3%
270,319
+328.5%
2.44%
+231.6%
ALKS BuyALKERMES PLC$3,543,265
+153.3%
126,500
+183.1%
2.38%
+150.5%
CRNX NewCRINETICS PHARMACEUTICALS INC$2,795,56094,000
+100.0%
1.87%
REPL NewREPLIMUNE GROUP INC$2,566,500150,000
+100.0%
1.72%
CNTA NewCENTESSA PHARMACEUTICALS PLCsponsored ads$2,092,068323,349
+100.0%
1.40%
OLMA BuyOLEMA PHARMACEUTICALS INC$1,889,636
+97.8%
153,007
+44.6%
1.27%
+95.7%
SRPT NewSAREPTA THERAPEUTICS INC$1,878,91015,500
+100.0%
1.26%
REPL NewREPLIMUNE GROUP INCcall$1,766,0001,000
+100.0%
1.18%
ETNB New89BIO INCcall$1,523,0001,000
+100.0%
1.02%
DYN BuyDYNE THERAPEUTICS INC$1,312,640
+59.8%
146,500
+100.7%
0.88%
+58.3%
KRON BuyKRONOS BIO INC$934,361
+72.5%
718,739
+128.2%
0.63%
+70.6%
BCLI NewBRAINSTORM CELL THERAPEUTICSput$825,0002,500
+100.0%
0.55%
IONS NewIONIS PHARMACEUTICALS INC$512,56811,300
+100.0%
0.34%
ETNB New89BIO INC$506,43232,800
+100.0%
0.34%
NewLEAP THERAPEUTICS INC$488,749354,166
+100.0%
0.33%
NewCELLECTAR BIOSCIENCES INC.$320,232121,300
+100.0%
0.22%
NewSTRUCTURE THERAPEUTICS INCsponsored ads$252,1005,000
+100.0%
0.17%
NewAN2 THERAPEUTICS INC$213,86413,300
+100.0%
0.14%
NewMARINUS PHARMECEUTICALS INC$156,97519,500
+100.0%
0.10%
MRSN NewMERSANA THERAPEUTICS INC$126,50199,607
+100.0%
0.08%
GLYC NewGLYCOMIMETIC INC$41,25027,500
+100.0%
0.03%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
IOVANCE BIOTHERAPEUTICS INC24Q1 202321.2%
IRIDEX CORP20Q3 20198.1%
ARROWHEAD PHARMACEUTICALS INC20Q2 20237.9%
IMMUNOMEDICS INC19Q3 202020.6%
VERACYTE INC19Q3 201910.1%
ASCENDIS PHARMA A S18Q2 20207.2%
XENON PHARMACEUTICALS INC18Q3 20224.6%
CAS MED SYS PAR $0.00418Q1 20196.4%
APELLIS PHARMACEUTICALS INC17Q3 202318.4%
KURA ONCOLOGY INC. COMMON STOCK17Q3 20238.1%

View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
ACUTA CAPITAL PARTNERS, LLC Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
BCLS Acquisition Corp.Sold outFebruary 14, 202300.0%
Jiya Acquisition Corp.Sold outFebruary 14, 202300.0%
VistaGen Therapeutics, Inc.Sold outFebruary 14, 202300.0%
Larimar Therapeutics, Inc.Sold outFebruary 15, 202200.0%
CATALYST BIOSCIENCES, INC.Sold outFebruary 14, 202200.0%
Aadi Bioscience, Inc.September 07, 20211,529,4027.2%
Kadmon Holdings, Inc.February 14, 20207,373,3334.6%
IRIDEX CORPSold outNovember 13, 201900.0%
ASSEMBLY BIOSCIENCES, INC.February 14, 2019718,5002.8%
CAS MEDICAL SYSTEMS INCFebruary 14, 20195,263,50818.2%

View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
SC 13G/A2023-02-14
SC 13G/A2023-02-14
SC 13G/A2023-02-14
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15

View ACUTA CAPITAL PARTNERS, LLC's complete filings history.

Compare quarters

Export ACUTA CAPITAL PARTNERS, LLC's holdings